Holen Sie sich die Stockscreener-App
7.06
8.95%
0.58
Vorhandelsmarkt:
7.13
0.07
+0.99%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.48
Offen:
$6.61
24-Stunden-Volumen:
1.84M
Relative Volume:
0.63
Marktkapitalisierung:
$322.48M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-8.506
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
+2.62%
1M Leistung:
-29.75%
6M Leistung:
-52.30%
1J Leistung:
+59.37%
1-Tages-Spanne:
$6.43
$7.08
1-Wochen-Bereich:
$6.19
$7.08
52-Wochen-Spanne:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.06 | 296.19M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
What makes Capricor Therapeutics Inc. stock price move sharplyFree Stock Market Entry Timing Signals - Newser
Relative strength of Capricor Therapeutics Inc. in sector analysisAI Entry Timing Prediction for Swing Traders - Newser
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky Before September 15, 2025 to Join Class Action - ACCESS Newswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
What are analysts’ price targets for Capricor Therapeutics Inc. in the next 12 monthsBuild your wealth with consistent stock growth - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - WV News
Investors who lost money on Capricor Therapeutics, Inc. - GlobeNewswire
CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Bluefield Daily Telegraph
CAPR Class Action Alert: Robbins LLP Reminds Investors of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Newsfile
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Should I buy Capricor Therapeutics Inc. stock before earningsHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Capricor Therapeutics Inc. stockUnstoppable trading performance - Autocar Professional
Is Capricor Therapeutics Inc. a good long term investmentSignificant capital appreciation - Autocar Professional
Investors who lost money on Capricor Therapeutics, - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Arizona State Retirement System Buys Shares of 11,707 Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Barchart.com
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Capricor Therapeutics, Inc. (CAPR) - TradingView
CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - ETX View
What drives Capricor Therapeutics Inc. stock priceOutperformance with explosive growth - jammulinksnews.com
Capricor Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsCAPR - Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Behind Capricor Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 15% loss last week hit both individual investors who own 47% as well as institutions - simplywall.st
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigatin - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shareholders of Class Action Lawsuit and September 15, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - StreetInsider
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Capricor Therapeutics, Inc.September 15, 2025 Deadline - ACCESS Newswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: - GlobeNewswire
Investor Sues Biotech Capricor After Product's FDA Denial - Law360
Levi & Korsinsky Urges Capricor Therapeutics, Inc. (CAPR) Shareholders to Act Before Lead Plaintiff Deadline September 15, 2025 - ACCESS Newswire
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):